子宫内膜异位症血浆蛋白生物标志物的鉴定及疾病诊断统计模型的开发
本研究比较了两个独立临床人群共805名参与者,通过蛋白质组学工作流程鉴定并验证了10种血浆蛋白生物标志物,并构建了三个多变量诊断模型。模型3(严重子宫内膜异位症 vs 症状性对照)表现最佳,AUC为0.997(95%CI 0.994-1.000);模型1的AUC为0.993(95%CI 0.988-0.998),模型2的AUC为0.729(95%CI 0.676-0.783)。这些标志物和模型可能成为子宫内膜异位症非侵入性诊断的新工具。
要点
- 鉴定并验证了10种血浆蛋白生物标志物,对子宫内膜异位症诊断具有较强预测准确性。
- 模型3区分严重子宫内膜异位症与症状性对照的AUC为0.997(95%CI 0.994-1.000)。
- 模型1区分子宫内膜异位症病例与一般人群对照的AUC为0.993(95%CI 0.988-0.998)。
核心结论
- 这些血浆蛋白生物标志物及由此产生的诊断模型可能成为子宫内膜异位症非侵入性诊断的新工具。
研究设计与样本
- 本研究比较了两个独立临床人群共805名参与者,所有子宫内膜异位症和症状性对照样本状态均经腹腔镜确认。
- 采用蛋白质组学工作流程鉴定和验证血浆蛋白生物标志物,随后开发靶向质谱 assay 比较464例子宫内膜异位症病例、153例一般人群对照和132例症状性对照的血浆样本。
- 构建了三个多变量模型:模型1(逻辑回归)用于子宫内膜异位症病例 vs 一般人群对照,模型2(逻辑回归)用于rASRM II至IV期(轻至重度)子宫内膜异位症病例 vs 症状性对照,模型3(随机森林)用于IV期(重度)子宫内膜异位症病例 vs 症状性对照。
主要发现
- 三个模型共鉴定出10种蛋白生物标志物,对临床因素有显著附加价值。
- 模型3(重度子宫内膜异位症 vs 症状性对照)表现最佳,AUC为0.997(95%CI 0.994-1.000)。
- 模型3应用于剩余数据集时能准确区分症状性对照与早期子宫内膜异位症(I至III期子宫内膜异位症的AUC≥0.85)。
- 模型1表现出较强预测性能,AUC为0.993(95%CI 0.988-0.998)。
- 模型2的AUC为0.729(95%CI 0.676-0.783)。
局限性
- 研究参与者大多为欧洲族裔,结果可能因对照组中未确诊的子宫内膜异位症而产生偏倚。
- 需要进一步分析以使研究结果能推广到其他人群和环境。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
STUDY QUESTION: Can a panel of plasma protein biomarkers be identified to accurately and specifically diagnose endometriosis? SUMMARY ANSWER: A novel panel of 10 plasma protein biomarkers was identified and validated, demonstrating strong predictive accuracy for the diagnosis of endometriosis. WHAT IS KNOWN ALREADY: Endometriosis poses intricate medical challenges for affected individuals and their physicians, yet diagnosis currently takes an average of 7 years and normally requires invasive laparoscopy. Consequently, the need for a simple, accurate non-invasive diagnostic tool is paramount. STUDY DESIGN, SIZE, DURATION: This study compared 805 participants across two independent clinical populations, with the status of all endometriosis and symptomatic control samples confirmed by laparoscopy. A proteomics workflow was used to identify and validate plasma protein biomarkers for the diagnosis of endometriosis. PARTICIPANTS/MATERIALS, SETTING, METHODS: A proteomics discovery experiment identified candidate biomarkers before a targeted mass spectrometry assay was developed and used to compare plasma samples from 464 endometriosis cases, 153 general population controls, and 132 symptomatic controls. Three multivariate models were developed: Model 1 (logistic regression) for endometriosis cases versus general population controls, Model 2 (logistic regression) for rASRM stage II to IV (mild to severe) endometriosis cases versus symptomatic controls, and Model 3 (random forest) for stage IV (severe) endometriosis cases versus symptomatic controls. MAIN RESULTS AND THE ROLE OF CHANCE: A panel of 10 protein biomarkers were identified across the three models which added significant value to clinical factors. Model 3 (severe endometriosis vs symptomatic controls) performed the best with an area under the receiver operating characteristic curve (AUC) of 0.997 (95% CI 0.994-1.000). This model could also accurately distinguish symptomatic controls from early-stage endometriosis when applied to the remaining dataset (AUCs ≥0.85 for stage I to III endometriosis). Model 1 also demonstrated strong predictive performance with an AUC of 0.993 (95% CI 0.988-0.998), while Model 2 achieved an AUC of 0.729 (95% CI 0.676-0.783). LIMITATIONS, REASONS FOR CAUTION: The study participants were mostly of European ethnicity and the results may be biased from undiagnosed endometriosis in controls. Further analysis is required to enable the generalizability of the findings to other populations and settings. WIDER IMPLICATIONS OF THE FINDINGS: In combination, these plasma protein biomarkers and resulting diagnostic models represent a potential new tool for the non-invasive diagnosis of endometriosis. STUDY FUNDING/COMPETING INTEREST(S): Subject recruitment at The Royal Women's Hospital, Melbourne, was supported in part by funding from the Australian National Health and Medical Research Council (NHMRC) project grants GNT1105321 and GNT1026033 and Australian Medical Research Future Fund grant no. MRF1199715 (P.A.W.R., S.H.-C., and M.H.). Proteomics International has filed patent WO 2021/184060 A1 that relates to endometriosis biomarkers described in this manuscript; S.B., R.L., and T.C. declare an interest in this patent. J.I., S.B., C.L., D.I., H.L., K.P., M.D., M.M., M.R., P.T., R.L., and T.C. are shareholders in Proteomics International. Otherwise, the authors have no conflicts of interest. TRIAL REGISTRATION NUMBER: N/A.
引用
- Schoeman EM, Bringans S, Peters K, et al. Identification of plasma protein biomarkers for endometriosis and the development of statistical models for disease diagnosis. Hum Reprod. 2025. PMID: 39719050. doi:10.1093/humrep/deae278
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。